Icon research teams at Icon Cancer Centre Hobart, Tasmania and Icon Cancer Centre Windsor Gardens, South Australia are the deserving recipients of ICF’s inaugural grants.
Read on to learn more about the recipients and their research projects.
Icon Cancer Foundation awards inaugural grants to innovative research teams
Not-for-profit cancer research charity, Icon Cancer Foundation (ICF) is thrilled to announce the funding of two innovative research projects at Icon Cancer Centre (Australia) aimed at enhancing patient care and improving treatment outcomes.
Associate Professor Louise Nott and Georgina Douglas | Icon Cancer Centre Hobart
A/Prof Louise Nott and Registered Nurse, Georgina Douglas will lead a clinical trial: COMPRES which investigates the use of compression therapy in patients’ hands and feet during treatment with Oxaliplatin, a chemotherapy drug known for causing painful nerve damage.
Principal Investigator, A/Prof Nott hopes this trial will benefit patients suffering severe side effects.
“Nerve damage, also known as peripheral neuropathy, can really impact a patient’s everyday living and quality of life,” A/Prof Nott said.
“This trial will help us identify if an intervention like compression therapy can prevent this side effect or minimise its effect on their physical and emotional well-being.”
Co-Investigator, Georgina Douglas says there is very limited research on preventative interventions to neurotoxic effects for patients treated with Oxaliplatin.
“Peripheral neuropathy is one of the most common side effects related to this particular chemotherapy,” Georgina said.
“It can be very painful for the patient and can also lead to terminating treatment early or reducing the dose.”
“Establishing a cost-effective, minimally invasive way to prevent this side effect would significantly enhance the quality of life for patients undergoing this type of chemotherapy.”
Associate Professor Peter Gorayski and Lydia Tamblyn | Icon Cancer Centre Windsor Gardens
A/Prof Peter Gorayski and Site Manager, Lydia Tamblyn will lead another innovative research project funded by ICF – a clinical registry study called Innovative Low-dose Radiation for OsteoArthritis Relief and Management (iROAR).
Principal Investigator and Radiation Oncologist, A/Prof Gorayski is excited to start this meaningful research.
“Our study, iROAR, represents a significant step forward in exploring non-invasive treatment options for osteoarthritis,” A/Prof Gorayski said.
“By evaluating the safety and efficacy of low-dose radiation therapy (LDRT), we aim to provide valuable data that could lead to improved quality of life for patients suffering from this common condition.
This research will also contribute to the growing body of real-world evidence, helping us understand how these therapies perform outside the controlled environment of clinical trials.”
Co-Investigator and the centre’s Site Manager, Lydia Tamblyn says this registry is important for people with osteoarthritis because it’s a potential effective treatment option that could help them feel better without needing surgery or taking medications long-term.
“Osteoarthritis can be very tough to live with, so finding new ways to treat it is crucial,” Lydia said.
“By having this registry, we will establish important relationships that may improve patient access to LDRT into the future.
“It’s a great example of how working together, we can make a real difference in healthcare,” Lydia said.
Future healthcare
Both the COMPRES trial and IROAR registry add to Icon Group’s longstanding commitment to clinical trials and research across our global network.
ICF work closely with Icon’s cancer centres across Australia to help fund innovative cancer research and clinical trials that benefit patients now and into the future. ICF looks forward to the impact these studies will have on patient treatment and care.
Learn more about Icon Cancer Foundation.
Learn more about research at Icon.
About Icon Group
Icon Group is Australia’s largest dedicated cancer care provider and has expanded globally into Singapore, Mainland China, Hong Kong and New Zealand.
Our people
People from across Icon Group share their stories of success, career progression and being iconic.
A career with Icon
At Icon, you’ll help change lives, every single day. In return for your passion, dedication and agility, we offer a workplace where you can.
Updates
Read the latest news and updates across Icon Group.